CS-2036 / CanSino - LARVOL DELTA

CTP-VLP-002: A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers (clinicaltrials.gov) - P1/2 | N=480 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease

CTP-VLP-002: A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers (clinicaltrials.gov) - P1/2 | N=480 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

CanSinoBIO Obtained Approval for Clinical Trials on DTcP-Hib-MCV4 Combined Vaccine (CanSinoBIO Press Release) - "CanSino Biologics Inc...is pleased to announce that it has obtained clinical trial approval from the National Medical Products Administration of the People’s Republic of China to initiate a clinical trial for its absorbed diphtheria, tetanus and acellular pertussis (components) (the 'DTcP') Haemophilus Influenzae Type b (Conjugate) (the 'Hib') - Group ACYW135 Meningococcal (Conjugate) (the 'MCV4') combined vaccine (the 'DTcP-Hib-MCV4 Combined Vaccine')...Additionally, the DTcP Infant vaccine is in Phase III clinical trials, and the Hib Vaccine is in Phase I clinical trials...Furthermore, CanSinoBIO is expanding its global innovative vaccine portfolio with its VLP-Polio vaccine, which is currently in Phase Ⅰ/Ⅱ clinical trials in Indonesia."

New trial • Infectious Disease

A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: CanSino Biologics Inc. | Active, not recruiting ➔ Completed | Trial primary completion date: Sep 2024 ➔ Mar 2024

Trial completion • Trial primary completion date • Infectious Disease

A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers (clinicaltrials.gov) - P1/2 | N=480 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P1/2 trial • Infectious Disease

A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease

A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P1 trial • Infectious Disease